JP2014523521A - リシルオキシダーゼ様２のアッセイおよびその使用の方法 - Google Patents

リシルオキシダーゼ様２のアッセイおよびその使用の方法 Download PDF

Info

Publication number
JP2014523521A
JP2014523521A JP2014513770A JP2014513770A JP2014523521A JP 2014523521 A JP2014523521 A JP 2014523521A JP 2014513770 A JP2014513770 A JP 2014513770A JP 2014513770 A JP2014513770 A JP 2014513770A JP 2014523521 A JP2014523521 A JP 2014523521A
Authority
JP
Japan
Prior art keywords
loxl2
antibody
disease
level
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014513770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523521A5 (enExample
Inventor
ビクトリア スミス，
ジョアン アイ． アダムケウィックス，
スーザン ケイ． ライマン，
ジェイソン チエン，
シャオミン リ，
リーシン シャオ，
ジェフリー ディー． ボーンスタイン，
Original Assignee
ギリアード バイオロジックス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46208194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2014523521(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ギリアード バイオロジックス， インコーポレイテッド filed Critical ギリアード バイオロジックス， インコーポレイテッド
Publication of JP2014523521A publication Critical patent/JP2014523521A/ja
Publication of JP2014523521A5 publication Critical patent/JP2014523521A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Silicon Polymers (AREA)
JP2014513770A 2011-06-01 2012-06-01 リシルオキシダーゼ様２のアッセイおよびその使用の方法 Withdrawn JP2014523521A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161492210P 2011-06-01 2011-06-01
US61/492,210 2011-06-01
US201161550895P 2011-10-24 2011-10-24
US61/550,895 2011-10-24
US201161578813P 2011-12-21 2011-12-21
US61/578,813 2011-12-21
PCT/US2012/040585 WO2012167181A1 (en) 2011-06-01 2012-06-01 Lysyl oxidase-like 2 assay and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016115175A Division JP2016164578A (ja) 2011-06-01 2016-06-09 リシルオキシダーゼ様２のアッセイおよびその使用の方法

Publications (2)

Publication Number Publication Date
JP2014523521A true JP2014523521A (ja) 2014-09-11
JP2014523521A5 JP2014523521A5 (enExample) 2015-06-18

Family

ID=46208194

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014513770A Withdrawn JP2014523521A (ja) 2011-06-01 2012-06-01 リシルオキシダーゼ様２のアッセイおよびその使用の方法
JP2016115175A Pending JP2016164578A (ja) 2011-06-01 2016-06-09 リシルオキシダーゼ様２のアッセイおよびその使用の方法
JP2017221000A Pending JP2018049033A (ja) 2011-06-01 2017-11-16 リシルオキシダーゼ様２のアッセイおよびその使用の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016115175A Pending JP2016164578A (ja) 2011-06-01 2016-06-09 リシルオキシダーゼ様２のアッセイおよびその使用の方法
JP2017221000A Pending JP2018049033A (ja) 2011-06-01 2017-11-16 リシルオキシダーゼ様２のアッセイおよびその使用の方法

Country Status (25)

Country Link
US (3) US20140206017A1 (enExample)
EP (1) EP2714744A1 (enExample)
JP (3) JP2014523521A (enExample)
KR (1) KR20140048156A (enExample)
CN (1) CN103946241A (enExample)
AP (1) AP2013007285A0 (enExample)
AR (1) AR086657A1 (enExample)
AU (2) AU2012261883A1 (enExample)
BR (1) BR112013030682A2 (enExample)
CA (1) CA2837534A1 (enExample)
CL (1) CL2013003445A1 (enExample)
CO (1) CO6940375A2 (enExample)
CR (1) CR20130657A (enExample)
EA (1) EA201391627A1 (enExample)
EC (1) ECSP13013092A (enExample)
IL (1) IL229631A0 (enExample)
MA (1) MA35212B1 (enExample)
MD (1) MD20130098A2 (enExample)
MX (1) MX2013013905A (enExample)
PE (1) PE20141450A1 (enExample)
PH (1) PH12013502490A1 (enExample)
TW (1) TW201319572A (enExample)
UY (1) UY34115A (enExample)
WO (1) WO2012167181A1 (enExample)
ZA (1) ZA201308812B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020514369A (ja) * 2017-03-16 2020-05-21 ノルディック・ビオサイエンス・エー／エスＮｏｒｄｉｃ Ｂｉｏｓｃｉｅｎｃｅ Ａ／Ｓ リシルオキシダーゼ様２アッセイ

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
BR112012019693A2 (pt) 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
WO2014070939A1 (en) * 2012-10-30 2014-05-08 Gilead Sciences, Inc. Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
WO2015187499A1 (en) 2014-06-03 2015-12-10 Gilead Sciences, Inc. Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor
EA201692202A1 (ru) 2014-06-11 2017-06-30 Джилид Сайэнс, Инк. Способы лечения сердечно-сосудистых заболеваний
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
JP2019510752A (ja) 2016-03-04 2019-04-18 ギリアード サイエンシーズ， インコーポレイテッド オートタキシン阻害剤の組成物及び合剤
JP2019513737A (ja) 2016-04-08 2019-05-30 ギリアード サイエンシーズ， インコーポレイテッド がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法
US20230152330A1 (en) * 2021-11-17 2023-05-18 AmMax Bio, Inc. Detection and treatment of idiopathic pulmonary fibrosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010038735A (ja) * 2008-08-05 2010-02-18 Terumo Corp 腹膜機能の評価方法および腹膜機能評価用イムノクロマト試験紙
JP2010535205A (ja) * 2007-08-02 2010-11-18 アレスト バイオサイエンシズ，インク． Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用
US20110044981A1 (en) * 2009-08-21 2011-02-24 Spangler Rhyannon Methods and compositions for treatment of pulmonary fibrotic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352862B1 (en) * 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
FI92882C (fi) * 1992-12-29 1995-01-10 Medix Biochemica Ab Oy Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi
US20030114410A1 (en) * 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
BR112012019693A2 (pt) * 2010-02-04 2017-06-20 Gilead Biologics Inc anticorpos que se ligam à lisil oxidase-like 2 (loxl2) e métodos de uso para eles.
US9556882B2 (en) * 2011-05-10 2017-01-31 Borgwarner Inc. Turbocharger with variable turbine geometry

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010535205A (ja) * 2007-08-02 2010-11-18 アレスト バイオサイエンシズ，インク． Ｌｏｘおよびｌｏｘｌ２阻害剤ならびにこれらの使用
JP2010038735A (ja) * 2008-08-05 2010-02-18 Terumo Corp 腹膜機能の評価方法および腹膜機能評価用イムノクロマト試験紙
US20110044981A1 (en) * 2009-08-21 2011-02-24 Spangler Rhyannon Methods and compositions for treatment of pulmonary fibrotic disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020514369A (ja) * 2017-03-16 2020-05-21 ノルディック・ビオサイエンス・エー／エスＮｏｒｄｉｃ Ｂｉｏｓｃｉｅｎｃｅ Ａ／Ｓ リシルオキシダーゼ様２アッセイ

Also Published As

Publication number Publication date
MX2013013905A (es) 2014-05-14
US20170269085A1 (en) 2017-09-21
AR086657A1 (es) 2014-01-15
KR20140048156A (ko) 2014-04-23
JP2016164578A (ja) 2016-09-08
IL229631A0 (en) 2014-01-30
AU2016244254A1 (en) 2016-11-03
MD20130098A2 (ro) 2014-06-30
AU2016244254B2 (en) 2018-10-18
NZ618682A (en) 2016-04-29
BR112013030682A2 (pt) 2016-12-06
UY34115A (es) 2013-01-03
WO2012167181A1 (en) 2012-12-06
CL2013003445A1 (es) 2014-07-25
AU2012261883A1 (en) 2013-05-02
AP2013007285A0 (en) 2013-11-30
ZA201308812B (en) 2014-08-27
JP2018049033A (ja) 2018-03-29
EA201391627A1 (ru) 2014-08-29
CR20130657A (es) 2014-05-16
US20120309020A1 (en) 2012-12-06
CO6940375A2 (es) 2014-05-09
PH12013502490A1 (en) 2014-01-20
MA35212B1 (fr) 2014-06-02
EP2714744A1 (en) 2014-04-09
CN103946241A (zh) 2014-07-23
TW201319572A (zh) 2013-05-16
US20140206017A1 (en) 2014-07-24
CA2837534A1 (en) 2012-12-06
PE20141450A1 (es) 2014-11-06
ECSP13013092A (es) 2014-08-29

Similar Documents

Publication Publication Date Title
JP2018049033A (ja) リシルオキシダーゼ様２のアッセイおよびその使用の方法
US20170327595A1 (en) Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
CN105556308B (zh) 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
Attallah et al. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients
US20100041069A1 (en) Methods for diagnosing and monitoring liver diseases
JP6812521B2 (ja) クロモグラニンａを検出するための免疫アッセイ法および抗体
JP7191813B2 (ja) 急性心不全に罹患している対象におけるうっ血を評価するためのアドレノメデュリン
CN101023356A (zh) 诊断肝纤维化的方法
US20200041506A1 (en) Kit for rapid diagnosis of asthma or allergy disease
WO2015174544A1 (ja) 精神疾患判定マーカー
Huang et al. Development of a fluorescence immunochromatography method for quantitative measurement of matrix metalloproteinase-9
US10048267B2 (en) Methods and compositions for assaying blood levels of legumain
EP3311164B1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
Macias et al. Combined use of aspartate aminotransferase, platelet count and matrix metalloproteinase 2 measurements to predict liver fibrosis in HIV/hepatitis C virus‐coinfected patients
JP7758661B2 (ja) 心不全を評価するためのアッセイ
Floraine The combination of Fibroscan with blood markers in the FibroMeterVCTE significantly reduces the use of liver biopsy for the assessment of advanced fibrosis in NAFLD
NZ618682B2 (en) Lysyl oxidase-like 2 assay and methods of use thereof
KR20220157443A (ko) Xix형 콜라겐 분석
TW202602930A (zh) 測量脂蛋白(a)之生物標記分析
HK1112506A (en) Method for diagnosing liver fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150427

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170215

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170405